{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T13:41:01Z","timestamp":1694526061751},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2002,4,19]],"date-time":"2002-04-19T00:00:00Z","timestamp":1019174400000},"content-version":"vor","delay-in-days":1053,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[1999,6]]},"abstract":"<jats:p><jats:bold>Background.<\/jats:bold> Ranitidine bismuth citrate (RBC), 400 mg bid for 4 weeks, plus clarithromycin, 500 mg tid, is a regimen approved by the US Food and Drug Administration for the eradication of <jats:italic>Helicobacter pylori<\/jats:italic> in patients with duodenal ulcers. Proof that the clarithromycin portion of the regimen could be given twice daily without loss of efficacy would reduce cost and improve patient compliance. The objective of this study was to compare the <jats:italic>H. pylori<\/jats:italic> eradication rates in patients who had duodenal ulcer and were randomly assigned to 4 weeks of treatment with RBC, 400 mg bid, in conjunction with 2 weeks of therapy with either clarithromycin, 500 mg tid, or clarithromycin, 500 mg bid.<\/jats:p><jats:p><jats:bold>Patients and Methods.<\/jats:bold> Patients who had a duodenal ulcer and were <jats:italic>H. pylori<\/jats:italic>\u2013positive by at least two tests were randomly assigned to (1) RBC, 400 mg bid for 4 weeks, plus clarithromycin, 500 mg tid for 2 weeks, or (2) RBC, 400 mg bid for 4 weeks, plus clarithromycin, 500 mg bid for 2 weeks. <jats:italic>H. pylori<\/jats:italic> eradication was assessed 4 weeks after completion of RBC plus clarithromycin<jats:italic>.<\/jats:italic><\/jats:p><jats:p><jats:bold>Results.<\/jats:bold> Three hundred eighty\u2010three patients from 78 centers had a duodenal ulcer and were <jats:italic>H. pylori<\/jats:italic>\u2013positive. The modified intent\u2010to\u2010treat (MITT) and the per\u2010protocol (PP) eradication rates were statistically equivalent between the twice\u2010daily (65% MITT, 74% PP) and thrice\u2010daily (63% MITT, 73% PP) clarithromycin treatment regimens. Incidence and types of adverse events did not differ between the two groups.<\/jats:p><jats:p><jats:bold>Conclusions.<\/jats:bold> For eradicating <jats:italic>H. pylori<\/jats:italic> in patients with duodenal ulcer, clarithromycin, 500 mg bid for 2 weeks, with RBC, 400 mg bid for 4 weeks, is equivalent to clarithromycin, 500 mg tid with RBC. The potential enhancement of patient compliance, reduced cost of clarithromycin, and equivalent efficacy would support the use of twice\u2010daily clarithromycin in triple\u2010therapy regimens with RBC.<\/jats:p>","DOI":"10.1046\/j.1523-5378.1999.98005.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:21:18Z","timestamp":1047424878000},"page":"121-127","source":"Crossref","is-referenced-by-count":2,"title":["Twice\u2010Daily Versus Thrice\u2010Daily Clarithromycin in Combination with Ranitidine Bismuth Citrate in the Eradication of <i>Helicobacter pylori<\/i>"],"prefix":"10.1111","volume":"4","author":[{"given":"Howard I.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa B.","family":"Perschy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"McSorley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan C.","family":"Sorrells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,4,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Conference.Helicobacter pyloriin peptic ulcer disease. JAMA 1994;272:65\u20139.","DOI":"10.1001\/jama.272.1.65"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-9-705"},{"key":"e_1_2_7_4_2","first-page":"24","article-title":"Helicobacter pylori and duodenal ulcer recurrence.","volume":"87","author":"Patchett S","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302043280503"},{"key":"e_1_2_7_6_2","doi-asserted-by":"crossref","unstructured":"Peterson WL Ciociola AA Sykes DL McSorley DJ Webb DD the RBCH. PyloriStudy Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers eradicatingH. pyloriand reducing ulcer recurrence. Aliment Pharmacol Ther 1996;10:251\u201361.","DOI":"10.1111\/j.0953-0673.1996.00251.x"},{"key":"e_1_2_7_7_2","first-page":"2213","article-title":"Randomized comparison of ranitidine bismuth citrate\u2013based triple therapies for Helicobacter pylori.","volume":"92","author":"Laine L","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_8_2","first-page":"246","article-title":"The influence of drug dosage on Helicobacter pylori eradication: A cost\u2010effectiveness analysis.","volume":"91","author":"Treiber G","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655298750027209"},{"key":"e_1_2_7_10_2","first-page":"A201","article-title":"Synergism study of ranitidine bismuth citrate and metronidazole against metronidazole\u2010resistant H. pylori clinical isolates.","volume":"112","author":"Lopez\u2010Brea M","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_7_11_2","first-page":"A1057","article-title":"Ranitidine bismuth citrate enhances clarithromycin activity against clinical isolates of H. pylori.","volume":"112","author":"Osato MS","year":"1997","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_2_7_12_2","first-page":"A12","article-title":"Ranitidine bismuth citrate can overcome in vitro antibiotic resistance in Helicobacter pylori.","volume":"41","author":"Midolo PD","year":"1997","journal-title":"Gut"},{"issue":"1","key":"e_1_2_7_13_2","first-page":"A104","article-title":"Overcoming clarithromycin resistance with the combination of clarithromycin and ranitidine bismuth citrate.","volume":"41","author":"Osato MS","year":"1997","journal-title":"Gut"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90095-G"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)23029-7"},{"key":"e_1_2_7_16_2","unstructured":"Drug Topics Red Book 1998;194."}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1523-5378.1999.98005.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1999.98005.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1523-5378.1999.98005.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.1999.98005.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:33:34Z","timestamp":1694403214000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1523-5378.1999.98005.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,6]]}},"alternative-id":["10.1046\/j.1523-5378.1999.98005.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-5378.1999.98005.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,6]]}}}